• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黏膜接种减毒活重组新冠病毒疫苗可保护非人灵长类动物免受新冠病毒感染。

Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.

作者信息

Tioni Mariana F, Jordan Robert, Pena Angie Silva, Garg Aditya, Wu Danlu, Phan Shannon I, Weiss Christopher M, Cheng Xing, Greenhouse Jack, Orekov Tatyana, Valentin Daniel, Kar Swagata, Pessaint Laurent, Andersen Hanne, Stobart Christopher C, Bloodworth Melissa H, Stokes Peebles R, Liu Yang, Xie Xuping, Shi Pei-Yong, Moore Martin L, Tang Roderick S

机构信息

Meissa Vaccines Inc, Redwood City, CA, USA.

Bill & Melinda Gates Foundation, Seattle, WA, USA.

出版信息

NPJ Vaccines. 2022 Jul 29;7(1):85. doi: 10.1038/s41541-022-00509-6.

DOI:10.1038/s41541-022-00509-6
PMID:35906244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9334537/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.

摘要

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是新冠疫情全球大流行的病原体。SARS-CoV-2是一种包膜RNA病毒，其进入宿主细胞依赖三聚体表面糖蛋白刺突。在此，我们描述了新冠疫苗候选株MV-014-212，这是一种减毒活重组人呼吸道合胞病毒，表达嵌合SARS-CoV-2刺突作为唯一的病毒包膜蛋白。MV-014-212在非洲绿猴（AGM）中具有减毒作用且具有免疫原性。在AGM中单次经黏膜给予MV-014-212可抵御SARS-CoV-2攻击，使鼻腔中SARS-CoV-2的峰值病毒载量降低200倍以上。MV-014-212可在鼻腔中诱导黏膜免疫球蛋白A，并在血清中诱导产生中和抗体，这些中和抗体对值得关注的病毒变体Alpha、Beta和Delta表现出交叉中和作用。像MV-014-212这样经鼻给药的减毒活疫苗生产成本低，适合全球推广。MV-014-212目前正作为一种经鼻新冠疫苗进行1期临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/d6287e8ab75f/41541_2022_509_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/1478d4307304/41541_2022_509_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/004456a38149/41541_2022_509_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/e45ffcbff034/41541_2022_509_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/0d95ae4006de/41541_2022_509_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/8862c1561253/41541_2022_509_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/d6287e8ab75f/41541_2022_509_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/1478d4307304/41541_2022_509_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/004456a38149/41541_2022_509_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/e45ffcbff034/41541_2022_509_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/0d95ae4006de/41541_2022_509_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/8862c1561253/41541_2022_509_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2692/9338042/d6287e8ab75f/41541_2022_509_Fig6_HTML.jpg

相似文献

1
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.黏膜接种减毒活重组新冠病毒疫苗可保护非人灵长类动物免受新冠病毒感染。
NPJ Vaccines. 2022 Jul 29;7(1):85. doi: 10.1038/s41541-022-00509-6.
2
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.鼻内给予一剂基于 MVA 的 COVID-19 候选疫苗可诱导局部和全身免疫应答，并可保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Sep 12;13:995235. doi: 10.3389/fimmu.2022.995235. eCollection 2022.
3
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.鼻腔接种疫苗诱导针对 SARS-CoV-2 变体的交叉保护分泌型 IgA 抗体，降低肺嗜酸性免疫病理学的潜在风险。
Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26.
4
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.用表达严重急性呼吸综合征冠状病毒刺突蛋白的减毒副流感病毒对非洲绿猴（非洲猕猴）进行黏膜免疫以预防严重急性呼吸综合征。
Lancet. 2004 Jun 26;363(9427):2122-7. doi: 10.1016/S0140-6736(04)16501-X.
5
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.鼻腔接种基于 MVA 的疫苗可诱导 IgA 并保护 hACE2 小鼠的呼吸道免受 SARS-CoV-2 感染。
Proc Natl Acad Sci U S A. 2022 Jun 14;119(24):e2202069119. doi: 10.1073/pnas.2202069119. Epub 2022 Jun 9.
6
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.单次免疫表达刺突蛋白和核衣壳蛋白的重组 ACAM2000 痘苗病毒可保护仓鼠免受 SARS-CoV-2 引起的临床疾病。
J Virol. 2022 May 11;96(9):e0038922. doi: 10.1128/jvi.00389-22. Epub 2022 Apr 12.
7
African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.非洲绿猴再现复制活减毒流感病毒候选疫苗的临床经验。
J Virol. 2014 Jul;88(14):8139-52. doi: 10.1128/JVI.00425-14. Epub 2014 May 7.
8
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.两种严重急性呼吸综合征（SARS）候选疫苗在感染SARS冠状病毒的小鼠中的比较评估。
J Gen Virol. 2006 Mar;87(Pt 3):641-650. doi: 10.1099/vir.0.81579-0.
9
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.鼻腔内给予表达 SARS-CoV-2 刺突蛋白的减毒活重组新城疫病毒可诱导高滴度中和抗体，并可预防仓鼠的实验性攻毒感染。
Vaccine. 2022 Aug 5;40(33):4676-4681. doi: 10.1016/j.vaccine.2022.07.005. Epub 2022 Jul 6.
10
Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2.一种针对新型冠状病毒的鼻内减毒活疫苗的免疫原性和保护效力
iScience. 2021 Sep 24;24(9):102941. doi: 10.1016/j.isci.2021.102941. Epub 2021 Aug 4.

引用本文的文献

1
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.不断演变的新冠病毒疫苗：从当前解决方案到广谱保护
Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.
2
Nasal vaccines for respiratory infections.用于呼吸道感染的鼻用疫苗。
Nature. 2025 May;641(8062):321-330. doi: 10.1038/s41586-025-08910-6. Epub 2025 May 7.
3
Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.诱导呼吸道黏膜免疫的新型疫苗策略：进展与影响

本文引用的文献

1
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.2021 年 7 月，马萨诸塞州巴恩斯特布尔县与大型公众集会相关的 SARS-CoV-2 感染暴发，包括 COVID-19 疫苗突破性感染。
MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.
2
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.鼻内接种 ChAdOx1 nCoV-19/AZD1222 疫苗可减少临床前模型中 SARS-CoV-2 D614G 挑战后的病毒脱落。
Sci Transl Med. 2021 Aug 18;13(607). doi: 10.1126/scitranslmed.abh0755. Epub 2021 Jul 27.
3
MedComm (2020). 2025 Jan 16;6(2):e70056. doi: 10.1002/mco2.70056. eCollection 2025 Feb.
4
Vaccines for Respiratory Viruses-COVID and Beyond.呼吸道病毒疫苗——新冠及其他。
Vaccines (Basel). 2024 Aug 22;12(8):936. doi: 10.3390/vaccines12080936.
5
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.基于纳米平台的鼻腔内疫苗：当前进展和临床挑战。
ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26.
6
The evolving landscape of live attenuated COVID-19 vaccines.新冠病毒减毒活疫苗的不断演变格局。
Nat Microbiol. 2024 Aug;9(8):1911-1913. doi: 10.1038/s41564-024-01770-2.
7
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗：黏膜疫苗接种与局部免疫的优势
Vaccines (Basel). 2024 Jul 18;12(7):795. doi: 10.3390/vaccines12070795.
8
Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.基于 SARS-CoV-2 刺突蛋白的鼻内疫苗在小鼠初次和加强免疫中的免疫原性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2364519. doi: 10.1080/21645515.2024.2364519. Epub 2024 Jun 16.
9
From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019.从肌肉注射到鼻腔给药：释放鼻喷式疫苗对抗2019冠状病毒病的潜力。
Clin Transl Immunology. 2024 May 20;13(5):e1514. doi: 10.1002/cti2.1514. eCollection 2024.
10
The Papain-like Protease Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Conjugated with Human Beta-Defensin 2 and Co1 Induces Mucosal and Systemic Immune Responses against the Virus.严重急性呼吸综合征冠状病毒2的木瓜蛋白酶样蛋白酶结构域与人β-防御素2和Co1结合可诱导针对该病毒的黏膜和全身免疫反应。
Vaccines (Basel). 2024 Apr 19;12(4):441. doi: 10.3390/vaccines12040441.
Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine.
用基于副流感病毒5的COVID-19疫苗单剂量黏膜免疫对K18-hACE2小鼠和雪貂进行SARS-CoV-2攻击保护。
Sci Adv. 2021 Jul 2;7(27). doi: 10.1126/sciadv.abi5246. Print 2021 Jul.
4
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.可扩展的活减 SARS-CoV-2 候选疫苗具有临床前安全性和有效性。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2102775118.
5
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?鼻内接种 SARS-CoV-2 疫苗：与肌肉内疫苗协同还是替代？
Int J Pharm. 2021 Jun 15;603:120686. doi: 10.1016/j.ijpharm.2021.120686. Epub 2021 May 6.
6
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets.SARS-CoV-2 刺突蛋白中的弗林裂解位点是在雪貂中传播所必需的。
Nat Microbiol. 2021 Jul;6(7):899-909. doi: 10.1038/s41564-021-00908-w. Epub 2021 Apr 27.
7
Animal models for SARS-CoV-2.用于 SARS-CoV-2 的动物模型。
Curr Opin Virol. 2021 Jun;48:73-81. doi: 10.1016/j.coviro.2021.03.009. Epub 2021 Apr 6.
8
Neutralizing Activity of BNT162b2-Elicited Serum.BNT162b2诱导血清的中和活性
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
9
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.BNT162b 疫苗可保护恒河猴免受 SARS-CoV-2 感染。
Nature. 2021 Apr;592(7853):283-289. doi: 10.1038/s41586-021-03275-y. Epub 2021 Feb 1.
10
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.一剂重组 VSV-∆G 棘突蛋白疫苗可提供针对 SARS-CoV-2 挑战的保护。
Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7.